SEARCH

SEARCH BY CITATION

References

  • 1
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74108.
  • 2
    Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC cancer base no. 5 version 2.0. Lyon, France: IARC Press, 2004.
  • 3
    Pisani P, Bray F, Parkin DM. Estimates of the worldwide prevalence of cancer for 25 cancers in the adult population. Int J Cancer 2002; 97: 7281.
  • 4
    Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst 1999; 91: 91632.
  • 5
    Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 7885.
  • 6
    de la Chapelle A. Genetic predisposition to colorectal cancer. Nat Rev Cancer 2004; 4: 76980.
  • 7
    Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 8607.
  • 8
    Jess T, Gamborg M, Matzen P, Munkholm P, Sørensen TI. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005; 100: 27249.
    Direct Link:
  • 9
    Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323: 122833.
  • 10
    Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, Chaussade S, Baron JA. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009; 101: 25666.
  • 11
    Wang D, DuBois RN. Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett 2008; 267: 197203.
  • 12
    Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Wu K, Fuchs CS. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 2008; 134: 218.
  • 13
    Hoffmeister M, Chang-Claude J, Brenner H. Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: a population-based case-control study. Int J Cancer 2007; 121: 132530.
  • 14
    Flossmann E, Rothwell PM. British doctors aspirin trial and the UK-TIA aspirin trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369: 160313.
  • 15
    Hoffmeister M, Chang-Claude J, Brenner H. Do older adults using NSAIDs have a reduced risk of colorectal cancer? Drugs Aging 2006; 23: 51323.
  • 16
    Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006; 6: 13040.
  • 17
    Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 8919.
  • 18
    Baron JA, Sandler RS. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med 2000; 51: 51123.
  • 19
    Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 25266.
  • 20
    Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001; 1: 1121.
  • 21
    Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD, Bigler J. PTGS2 (COX-2)-765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 2005; 14: 61619.
  • 22
    Poole EM, Bigler J, Whitton J, Sibert JG, Potter JD, Ulrich CM. Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev 2006; 15: 5028.
  • 23
    Ulrich CM, Bigler J, Sparks R, Whitton J, Sibert JG, Goode EL, Yasui Y, Potter JD. Polymorphisms in PTGS1 (=COX-1) and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev 2004; 13: 88993.
  • 24
    Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O, Langenbach R. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000; 60: 47058.
  • 25
    Poole EM, Bigler J, Whitton J, Sibert JG, Kulmacz RJ, Potter JD, Ulrich CM. Genetic variability in prostaglandin synthesis, fish intake and risk of colorectal polyps. Carcinogenesis 2007; 28: 125963.
  • 26
    Fries S, Grosser T, Price TS, Lawson JA, Kapoor S, DeMarco S, Pletcher MT, Wiltshire T, FitzGerald GA. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 2006; 130: 5564.
  • 27
    Maree AO, Curtin RJ, Chubb A, Dolan C, Cox D, O'Brien J, Crean P, Shields DC, Fitzgerald DJ. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005; 3: 23405.
  • 28
    Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 2003; 73: 12230.
  • 29
    Cross JT, Poole EM, Ulrich CM. A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia. Pharmacogenomics J 2008; 8: 23747.
  • 30
    Lukasiak S, Schiller C, Oehlschlaeger P, Schmidtke G, Krause P, Legler DF, Autschbach F, Schirmacher P, Breuhahn K, Groettrup M. Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon. Oncogene 2008; 27: 606874.
  • 31
    Li Z, Jansen M, Pierre SR, Figueiredo-Pereira ME. Neurodegeneration: linking ubiquitin/proteasome pathway impairment with inflammation. Int J Biochem Cell Biol 2003; 35: 54752.
  • 32
    Lee CG, Ren J, Cheong IS, Ban KH, Ooi LL, Yong Tan S, Kan A, Nuchprayoon I, Jin R, Lee KH, Choti M, Lee LA. Expression of the FAT10 gene is highly upregulated in hepatocellular carcinoma and other gastrointestinal and gynecological cancers. Oncogene 2003; 22: 2592603.
  • 33
    Ji F, Jin X, Jiao CH, Xu QW, Wang ZW, Chen YL. FAT10 level in human gastric cancer and its relation with mutant p53 level, lymph node metastasis and TNM staging. World J Gastroenterol 2009; 15: 222833.
  • 34
    Zhang DW, Jeang KT, Lee CG. p53 negatively regulates the expression of FAT10, a gene upregulated in various cancers. Oncogene 2006; 25: 231827.
  • 35
    Castellanos-Rubio A, Santin I, Irastorza I, Sanchez-Valverde F, Castaño L, Vitoria JC, Bilbao JR. A regulatory single nucleotide polymorphism in the ubiquitin D gene associated with celiac disease. Hum Immunol 2010; 71: 969.
  • 36
    Phang JM, Pandhare J, Liu Y. The metabolism of proline as microenvironmental stress substrate. J Nutr 2008; 138: 2008S15S.
  • 37
    Liu Y, Borchert GL, Surazynski A, Phang JM. Proline oxidase, a p53-induced gene, targets COX-2/PGE2 signaling to induce apoptosis and inhibit tumor growth in colorectal cancers. Oncogene 2008; 27: 672937.
  • 38
    Bender HU, Almashanu S, Steel G, Hu CA, Lin WW, Willis A, Pulver A, Valle D. Functional consequences of PRODH missense mutations. Am J Hum Genet 2005; 76: 40920.
  • 39
    Kempf L, Nicodemus KK, Kolachana B, Vakkalanka R, Verchinski BA, Egan MF, Straub RE, Mattay VA, Callicott JH, Weinberger DR, Meyer-Lindenberg A. Functional polymorphisms in PRODH are associated with risk and protection for schizophrenia and fronto-striatal structure and function. PLoS Genet 2008; 4: e1000252:19.
  • 40
    Willis A, Bender HU, Steel G, Valle D. PRODH variants and risk for schizophrenia. Amino Acids 2008; 35: 6739.
  • 41
    Zinkstok J, Schmitz N, van Amelsvoort T, Moeton M, Baas F, Linszen D. Genetic variation in COMT and PRODH is associated with brain anatomy in patients with schizophrenia. Genes Brain Behav 2008; 7: 619.
  • 42
    Brenner H, Chang-Claude J, Seiler CM, Stürmer T, Hoffmeister M. Does a negative screening colonoscopy ever need to be repeated? Gut 2006; 55: 114550.
  • 43
    Lilla C, Verla-Tebit E, Risch A, Jäger B, Hoffmeister M, Brenner H, Chang-Claude J. Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associated with exposure to tobacco smoke and meat consumption. Cancer Epidemiol Biomarkers Prev 2006; 15: 99107.
  • 44
    Lopez R, Silventoinen V, Robinson S, Kibria A, Gish W. WU-Blast2 server at the European bioinformatics institute. Nucleic Acids Res 2003; 31: 37958.
  • 45
    Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N. Combinatorial microRNA target predictions. Nat Genet 2005; 37: 495500.
  • 46
    Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res 2002; 30: 3894900.
  • 47
    Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009; 4: 107381.
  • 48
    Yue P, Melamud E, Moult J. SNPs3D: candidate gene and SNP selection for association studies. BMC Bioinformatics 2006; 7: 166:115.
  • 49
    Yue P, Moult J. Identification and analysis of deleterious human SNPs. J Mol Biol 2006; 356: 126374.
  • 50
    Yuan HY, Chiou JJ, Tseng WH, Liu CH, Liu CK, Lin YJ, Wang HH, Yao A, Chen YT, Hsu CN. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res 2006; 34: W635W641.
  • 51
    Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 22259.
  • 52
    Kormann MS, Carr D, Klopp N, Illig T, Leupold W, Fritzsch C, Weiland SK, von Mutius E, Kabesch M. G-protein-coupled receptor polymorphisms are associated with asthma in a large German population. Am J Respir Crit Care Med 2005; 171: 135862.
  • 53
    Dupont WD, Plummer WD, Jr. Power and sample size calculations for studies involving linear regression. Control Clin Trials 1998; 19: 589601.
  • 54
    Küry S, Buecher B, Robiou-du-Pont S, Scoul C, Colman H, Le Neel T, Le Houérou C, Faroux R, Ollivry J, Lafraise B, Chupin LD, Sébille V, et al. Low-penetrance alleles predisposing to sporadic colorectal cancers: a French case-controlled genetic association study. BMC Cancer 2008; 8: 326:114.
  • 55
    Gong Z, Bostick RM, Xie D, Hurley TG, Deng Z, Dixon DA, Zhang J, Hebert JR. Genetic polymorphisms in the cyclooxygenase-1 and cyclooxygenase-2 genes and risk of colorectal adenoma. Int J Colorectal Dis 2009; 24: 64754.
  • 56
    Hubner RA, Muir KR, Liu JF, Logan RF, Grainge MJ, Houlston RS. Members of the UKCAP Consortium. Polymorphisms in PTGS1, PTGS2 and IL-10 do not influence colorectal adenoma recurrence in the context of a randomized aspirin intervention trial. Int J Cancer 2007; 121: 20014.
  • 57
    Siezen CL, Bueno-de-Mesquita HB, Peeters PH, Kram NR, van Doeselaar M, van Kranen HJ. Polymorphisms in the genes involved in the arachidonic acid-pathway, fish consumption and the risk of colorectal cancer. Int J Cancer 2006; 119: 297303.
  • 58
    Siezen CL, Tijhuis MJ, Kram NR, van Soest EM, de Jong DJ, Fodde R, van Kranen HJ, Kampman E. Protective effect of nonsteroidal anti-inflammatory drugs on colorectal adenomas is modified by a polymorphism in peroxisome proliferator-activated receptor delta. Pharmacogenet Genomics 2006; 16: 4350.
  • 59
    Sansbury LB, Bergen AW, Wanke KL, Yu B, Caporaso NE, Chatterjee N, Ratnasinghe L, Schatzkin A, Lehman TA, Kalidindi A, Modali R, Lanza E. Inflammatory cytokine gene polymorphisms, nonsteroidal anti-inflammatory drug use, and risk of adenoma polyp recurrence in the polyp prevention trial. Cancer Epidemiol Biomarkers Prev 2006; 15: 494501.
  • 60
    Hansen-Petrik MB, McEntee MF, Jull B, Shi H, Zemel MB, Whelan J. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res 2002; 62: 4038.
  • 61
    Ulrich CM, Bigler J, Sibert J, Greene EA, Sparks R, Carlson CS, Potter JD. Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations. Hum Mutat 2002; 20: 40910.
  • 62
    Akashi H. Gene expression and molecular evolution. Curr Opin Genet Dev 2001; 11: 6606.
  • 63
    Karlin S, Mrázek J. What drives codon choices in human genes? J Mol Biol 1996; 262: 45972.